<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Biotech &amp; Pharma on OptionRaft - Trading &amp; Options Insights</title>
    <link>https://optionraft.com/categories/biotech--pharma/</link>
    <description>Recent content in Biotech &amp; Pharma on OptionRaft - Trading &amp; Options Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 11:03:05 +0000</lastBuildDate>
    <atom:link href="https://optionraft.com/categories/biotech--pharma/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Lilly&#39;s $2.75B Insilico Deal: AI Pharma Goes Mainstream</title>
      <link>https://optionraft.com/posts/eli-lilly-reaches-2-75-billion-deal-with-insilico-to-bring-ai-developed-drugs-to-the-global-market/</link>
      <pubDate>Tue, 31 Mar 2026 11:03:05 +0000</pubDate>
      <guid>https://optionraft.com/posts/eli-lilly-reaches-2-75-billion-deal-with-insilico-to-bring-ai-developed-drugs-to-the-global-market/</guid>
      <description>Eli Lilly reaches a $2.75 billion deal with Insilico Medicine. What this blockbuster AI-drug partnership means for LLY investors and biotech traders.</description>
    </item>
  </channel>
</rss>
